Effects of HFOT on Exercise Performance in Patients With COPD. A Randomized, Controlled Trial.

PHASE4CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

May 20, 2019

Primary Completion Date

August 2, 2019

Study Completion Date

August 2, 2019

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
COMBINATION_PRODUCT

High-flow oxygen therapy (HFOT)

HFOT will be applied by a dedicated large bore nasal cannula (Optiflow+, Fisher\&Paykel, New Zealand) at a flow rate 60 L/min, FiO2 45%, temperature 32 °C, using a HFOT device (myAIRVO2, Fisher\&Paykel, New Zealand).

COMBINATION_PRODUCT

Low-flow oxygen therapy (LFOT)

LFOT will be provided by a standard nasal cannula at a flow rate of 3 L/min using an oxygen concentrator (EverFlow, Philips Respironics).

Trial Locations (1)

Unknown

National Center of Cardiology and Internal Medicine, Bishkek

All Listed Sponsors
collaborator

National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov

OTHER_GOV

lead

University of Zurich

OTHER

NCT03955770 - Effects of HFOT on Exercise Performance in Patients With COPD. A Randomized, Controlled Trial. | Biotech Hunter | Biotech Hunter